Find information on thousands of medical conditions and prescription drugs.

Porphyria cutanea tarda

Porphyria cutanea tarda is the most common type of porphyria. The disorder results from low levels of the enzyme responsible for the fifth step in heme production. Heme is a vital molecule for all of the body's organs. It is a component of hemoglobin, the molecule that carries oxygen in the blood. Porphyria cutanea tarda is a subtype of porphyria. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Arthritis
Arthritis
Bubonic plague
Hypokalemia
Pachydermoperiostosis
Pachygyria
Pacman syndrome
Paget's disease of bone
Paget's disease of the...
Palmoplantar Keratoderma
Pancreas divisum
Pancreatic cancer
Panhypopituitarism
Panic disorder
Panniculitis
Panophobia
Panthophobia
Papilledema
Paraganglioma
Paramyotonia congenita
Paraphilia
Paraplegia
Parapsoriasis
Parasitophobia
Parkinson's disease
Parkinson's disease
Parkinsonism
Paroxysmal nocturnal...
Patau syndrome
Patent ductus arteriosus
Pathophobia
Patterson...
Pediculosis
Pelizaeus-Merzbacher disease
Pelvic inflammatory disease
Pelvic lipomatosis
Pemphigus
Pemphigus
Pemphigus
Pendred syndrome
Periarteritis nodosa
Perinatal infections
Periodontal disease
Peripartum cardiomyopathy
Peripheral neuropathy
Peritonitis
Periventricular leukomalacia
Pernicious anemia
Perniosis
Persistent sexual arousal...
Pertussis
Pes planus
Peutz-Jeghers syndrome
Peyronie disease
Pfeiffer syndrome
Pharmacophobia
Phenylketonuria
Pheochromocytoma
Photosensitive epilepsy
Pica (disorder)
Pickardt syndrome
Pili multigemini
Pilonidal cyst
Pinta
PIRA
Pityriasis lichenoides...
Pityriasis lichenoides et...
Pityriasis rubra pilaris
Placental abruption
Pleural effusion
Pleurisy
Pleuritis
Plummer-Vinson syndrome
Pneumoconiosis
Pneumocystis jiroveci...
Pneumocystosis
Pneumonia, eosinophilic
Pneumothorax
POEMS syndrome
Poland syndrome
Poliomyelitis
Polyarteritis nodosa
Polyarthritis
Polychondritis
Polycystic kidney disease
Polycystic ovarian syndrome
Polycythemia vera
Polydactyly
Polymyalgia rheumatica
Polymyositis
Polyostotic fibrous...
Pompe's disease
Popliteal pterygium syndrome
Porencephaly
Porphyria
Porphyria cutanea tarda
Portal hypertension
Portal vein thrombosis
Post Polio syndrome
Post-traumatic stress...
Postural hypotension
Potophobia
Poxviridae disease
Prader-Willi syndrome
Precocious puberty
Preeclampsia
Premature aging
Premenstrual dysphoric...
Presbycusis
Primary biliary cirrhosis
Primary ciliary dyskinesia
Primary hyperparathyroidism
Primary lateral sclerosis
Primary progressive aphasia
Primary pulmonary...
Primary sclerosing...
Prinzmetal's variant angina
Proconvertin deficiency,...
Proctitis
Progeria
Progressive external...
Progressive multifocal...
Progressive supranuclear...
Prostatitis
Protein S deficiency
Protein-energy malnutrition
Proteus syndrome
Prune belly syndrome
Pseudocholinesterase...
Pseudogout
Pseudohermaphroditism
Pseudohypoparathyroidism
Pseudomyxoma peritonei
Pseudotumor cerebri
Pseudovaginal...
Pseudoxanthoma elasticum
Psittacosis
Psoriasis
Psychogenic polydipsia
Psychophysiologic Disorders
Pterygium
Ptosis
Pubic lice
Puerperal fever
Pulmonary alveolar...
Pulmonary hypertension
Pulmonary sequestration
Pulmonary valve stenosis
Pulmonic stenosis
Pure red cell aplasia
Purpura
Purpura, Schoenlein-Henoch
Purpura, thrombotic...
Pyelonephritis
Pyoderma gangrenosum
Pyomyositis
Pyrexiophobia
Pyrophobia
Pyropoikilocytosis
Pyrosis
Pyruvate kinase deficiency
Uveitis
Q
R
S
T
U
V
W
X
Y
Z
Medicines

When signs and symptoms occur, they usually begin in adulthood and result from the skin becoming overly sensitive to sunlight. Areas of skin exposed to the sun develop severe blistering, scarring, changes in pigmentation, and increased hair growth. Exposed skin becomes fragile and is easily damaged. People with porphyria cutanea tarda also have increased iron levels in the liver. They face a higher risk of developing abnormal liver function and liver cancer. The signs and symptoms of this condition are triggered by nongenetic factors such as alcohol abuse, excess iron, certain hormones, and viral infections.

Epidemiology

This type of porphyria occurs in an estimated 1 in 25,000 people, including both inherited and sporadic (noninherited) cases. An estimated 80 % of porphyria cutanea tarda cases are sporadic. The exact frequency is not clear because many people with the condition never experience symptoms.

Genetics

Inherited mutations in the UROD gene cause about 20 % of cases. (The other 80 % of cases do not have mutations in UROD, and are classified as sporadic.) UROD makes an enzyme called uroporphyrinogen decarboxylase, which is critical to the chemical process that leads to heme production. The activity of this enzyme is usually reduced by 50 % in all tissues in people with the inherited form of the condition.

Nongenetic factors such as alcohol abuse, excess iron, and others listed above can increase the demand for heme and the enzymes required to make heme. The combination of this increased demand and reduced activity of uroporphyrinogen decarboxylase disrupts heme production and allows byproducts of the process to accumulate in the body, triggering the signs and symptoms of porphyria cutanea tarda.

The HFE gene makes a protein that helps cells regulate the absorption of iron from the digestive tract and into the cells of the body. Certain mutations in the HFE gene cause hemochromatosis (an iron overload disorder). People who have these mutations are also at an increased risk of developing porphyria cutanea tarda.

In the 20% of cases where porphyria cutanea tarda is inherited, it is inherited in an autosomal dominant pattern, which means one copy of the altered gene is sufficient to decrease enzyme activity and cause the signs and symptoms of the disorder.

Read more at Wikipedia.org


[List your site here Free!]


Dioxin toxicity and chloracne in the Ukraine
From Journal of Drugs in Dermatology, 3/1/05 by J. Barton Sterling

Abstract

Dioxin toxicity can lead to severe cutaneous and systemic disease. The poisoning of Ukrainian President Viktor Yushchenko dramatically illustrates the damage dioxin can inflict. The hallmark of dioxin toxicity is chloracne and should alert the clinician to this diagnosis, which can be confirmed by blood tests. Olestra, a non-absorbable, non-digestible fat substitute is a promising new treatment to lower systemic dioxin levels.

**********

Introduction

In early September 2004, Ukrainian presidential candidate Viktor Yushchenko believed he was poisoned at a dinner party. About 3 hours after dinner, he complained of a headache and the next day developed an acute stomach ache. Five days later, he arrived at the hospital unable to walk. Blood tests revealed a high white blood cell count and elevated liver enzymes. Scans showed that the liver, pancreas, and intestines were swollen. Endoscopy showed multiple intestinal ulcerations.

Tests for common poisons were negative and Yushchenko gradually recovered and returned to the campaign trail. Political opponents attributed the illness to bad sushi or too much alcohol.

Soon, however, he developed acneiform lesions on the face and trunk. He also suffered from severe back pain requiring epidural anesthesia. Gradually, over the next month, the skin lesions worsened to confluent cysts and nodules--hallmarks of chloracne (Figure 1). Blood samples were taken showing 100,000 units per gram of blood fat of the most harmful known dioxin, TCDD--the second highest concentration in a human on record.

Despite the disfigurement caused by dioxin poisoning, Yushchenko won the presidential election. The long-term internal effects of dioxin poisoning of this severity are unknown. He will suffer from chloracne for years, or even decades.

Dioxins

Dioxins are byproducts of manufacturing processes that utilize chlorine, such as in the manufacturing of herbicides, paper, and pulp bleaching. Waste incinerators also produce dioxin as a byproduct. As a result of its wide use in manufacturing and the contamination of soil and water, most people in the United States and Europe have small amounts of a mix of several dioxins in their bodies (15-45 units per gram of blood fat).

Of the hundreds of dioxins, TCDD is the most harmful. TCDD is chemically known as 2,3,7,8-tetrachlorodibenzoparadioxin and was the main component in Agent Orange. Agent Orange was an herbicide used during the Vietnam War to clear vegetation and expose the enemy. The herbicide became well known after the war for the myriad of health problems attributed to its use.

TCDD currently serves no commercial purpose. Pure TCDD must be manufactured in a laboratory. It is made in labs in Europe, Russia, and the United States for use as a control for measuring dioxin levels.

The fact that pure TCDD was found in Ukrainian President Viktor Yushchenko's blood suggests that he was poisoned.

Health Effects of Dioxin

In large doses, dioxin is one of the most toxic synthetic compounds. At a similar dose, TCDD is more toxic than cyanide, cantharidin, nicotine, or colchicine. (1)

The most common acute adverse effect of TCDD exposure is liver damage resembling viral hepatitis. Conjunctivitis, hypertriglyceridemia, prolonged protime, thrombocytopenia, diarrhea, porphyria cutanea tarda, hyperpigmentation, hirsutism, polyneuropathies, and depression may also occur. (2)

The long-term health effects of dioxin poisoning in humans have not been conclusively proven. After the Vietnam War, many alleged that dioxin was the cause of malignant tumors, sterility, abortion, and birth defects. However, no clearly defined mutagenic effects have been demonstrated in humans. Only in doses that cause considerable systemic toxicity has TCDD been shown to cause cancer in rats. (1)

[FIGURE 1A OMITTED]

The most extensive experience with TCDD in humans involves the residents of Seveso, Italy. In 1976, TCDD was released in a plume from a chemical plant when a safety disk ruptured. More than 37,000 persons were exposed to varying amounts of TCDD. Except for chloracne, no significant long-term health problems or pathologic laboratory parameters were found after 20 years of observation. (3)

Chloracne

Chloracne is the hallmark of dioxin toxicity. The term was introduced in 1899 by Herxheimer who believed this acneiform eruption was due to chlorine gas involved in the production of herbicides and wood preservatives. (4) Although some individuals seem to be resistant, the great majority of patients exposed to toxic doses of dioxin will exhibit chloracne.

[FIGURE 1B OMITTED]

The clinical course of chloracne varies. Usually 2 to 4 weeks after initial exposure, the patient will develop open comedones evolving into noninflammatory yellow cysts. These cysts appear on the malar cheeks, lateral to the eyes, and behind the ears. With more severe or chronic exposure, the cysts become inflammatory and spread to the trunk and genitalia. Usually the nose and limbs are spared. Lesions tend to persist for decades, especially on the malar cheeks and behind the ears. Scarring may be severe. (5)

Chloracne differs from acne vulgaris in a number of ways. Initial lesions of chloracne are open comedones and there are very few pustules or nodular lesions as in acne vulgaris. Sebaceous glands tend to undergo atrophy in chloracne, whereas in acne vulgaris there is increased sebaceous gland activity. Further, meibomian glands tend to be involved in chloracne, but not acne vulgaris. Finally, chloracne can occur in any age group unlike acne vulgaris which favors adolescence. (1)

The diagnosis of chloracne cannot be made from the histological study of skin biopsies. Pathology similar to severe acne vulgaris is seen. (2)

Treatment of chloracne is usually unsatisfactory and consists of oral isotretinoin, topical retinoids, and oral antibiotics. If exposure ceases, lesions will gradually improve over many years or decades.

Outcome of the Patient with the Highest Recorded Blood Level of TCCD and a Novel Therapy

In 1997, a 30-year-old secretary had the highest recorded systemic levels of TCDD (144,000 units per gram of blood fat). (6) She was believed to have orally ingested TCDD at the chemical laboratory where she worked. During the first year after exposure, the patient had centrofacial inflammation and acne that gradually progressed to dense cysts covering the entire face with only a few lesions on the body. Over the next year, the patient's entire skin surface became covered with inflamed, painful cysts. The patient also developed palmoplantar keratoderma, which had not been previously reported as a manifestation of dioxin poisoning. In addition to skin disease, the patient suffered from chronic gastrointestinal pain with a resultant 10-kg weight loss and amenorrhea. The patient was treated unsuccessfully with a total cumulative dose of 13 g of isotretinoin (0.7 mg/kg body weight/day). She was then managed with oral antibiotics, methylprednisolone, and analgesics. The patient has required repeat surgical intervention for deep inflammation and cysts.

Interestingly, an exposed colleague of the patient who also had high levels of TCDD (26,000 units per gram of blood fat) experienced only mild symptoms with comedones and cysts limited to the malar crease which cleared with topical tretinoin.

A promising new approach to lowering blood TCDD levels was employed on both patients. Olestra, a non-absorbable, non-digestible fat substitute was given. The authors reported that TCDD levels decreased 8 to 10-fold using Olestra, reducing TCDD half life from about 7 to 1-2 years. (7)

Conclusion

Chloracne is the hallmark of dioxin toxicity and should alert the clinician to the diagnosis. The clinical severity of chloracne can vary significantly. Levels of TCDD can be measured in the blood to confirm the diagnosis. Therapy for chloracne is often unsatisfactory. Olestra is a promising new treatment for lowering systemic dioxin levels.

References

1. Dunagin WG. Cutaneous signs of systemic toxicity due to dioxins and related chemicals. J Am Acad Dermatol. 1984;10:688-700.

2. Health effects of Agent Orange and dioxin contaminants. JAMA. 1982;248(15):1895-7.

3. Mocarelli P, Garthoux PM, Brambilla P, et al. Dioxin health effects on humans twenty years after Seveso: a summary. In: Chemistry, Man, and Environment: the Seveso Accident 20 Years on Monitoring, Epidemiology, and Remediation. New York: Elsevier; 1999;41-51.

4. Carson K. Chloracne and other manifestations of dioxin toxicity. In: Demis DJ, ed. Clinical Dermatology. Philadelphia, Lippincott-Raven; 1995.

5. Tindal J. Chloracne and chloracnegens. J Am Acad Dermatol. 1985;13:539-558.

6. Geusau A, Abraham K, Geissier K, Sator M, Stingl G, Tschachler E. Severe 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) intoxication: clinical and laboratory effects. Environ Health Perspect. 2001;109:865-869.

7. Geusau A, Tschachler E, Meixner M, Sandermann S, Papke O, et al. Olestra increases faecal excretion of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Lancet. 1999;354:1266-1269.

J. Barton Sterling MD, C. William Hanke, MD, MPH, FACP

Laser and Skin Surgery Center of Indiana

Address for Correspondence

C. William Hanke, MD, MPH, FACP

Laser and Skin Surgery Center of Indiana

13450 N. Meridian, Suite 355

Carmel, IN 46032

317-582-8484

E-mail: cwmhanke@sbcglobal.net

COPYRIGHT 2005 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2005 Gale Group

Return to Porphyria cutanea tarda
Home Contact Resources Exchange Links ebay